Beacon Therapeutics Reports P-II (DAWN) Trial Data on Laru-Zova in X-Linked Retinitis Pigmentosa (XLRP)

Why It Matters

The trial provides the first evidence that a sequential AAV‑based gene therapy can further enhance visual function in XLRP, potentially expanding treatment options for a disease with limited therapies. Success could accelerate regulatory pathways and solidify Beacon’s position in the emerging ocular‑gene‑therapy market.

Key Takeaways

• Phase‑2 DAWN trial shows sustained LLVA improvements at 12 months
• High‑dose cohort: 50% achieved ≥2‑line vision gain; 25% ≥3 lines
• Low‑dose group: 67% attained ≥2‑line improvement in LLVA
• VISTA P‑II/III trial to deliver topline results in H2‑2026

Pulse Analysis

X‑linked retinitis pigmentosa (XLRP) remains one of the most debilitating inherited retinal disorders, with patients losing night vision and peripheral sight early in life. Traditional interventions have been limited to supportive care, while gene‑replacement strategies using adeno‑associated virus (AAV) vectors have emerged as a promising avenue. Beacon Therapeutics’ laru‑zova employs an AAV vector to deliver a functional RPGR gene, building on earlier single‑dose therapies but aiming to boost durability and functional outcomes through a second‑generation construct.

The DAWN Phase‑2 data, presented at ARVO 2026, reveal that a second AAV‑mediated dose can produce measurable gains in low‑luminance visual acuity (LLVA) and microperimetry sensitivity after 12 months. High‑dose participants saw a 50% rate of at least two‑line improvement, with 25% achieving three‑line gains, while low‑dose subjects posted a 67% two‑line response. These efficacy signals, coupled with a favorable safety profile, suggest that sequential dosing may overcome the plateau observed in earlier monotherapy trials, offering a new therapeutic paradigm for progressive retinal degeneration.

Looking ahead, Beacon’s ongoing VISTA Phase‑II/III trial will test broader dosing regimens and longer follow‑up, with topline results slated for the latter half of 2026. If the efficacy trends hold, the company could be positioned for an accelerated FDA review, potentially securing a first‑in‑class indication for XLRP. The market impact would be significant, as investors and ophthalmology specialists watch for a scalable gene‑therapy model that could be adapted to other inherited retinal diseases, reinforcing the broader momentum in ocular biotech innovation.